What is the price-to-earnings ratio of Pharmaust?
The price-earnings ratio of Pharmaust is currently -3.88.
Pharmaust P/E 2024
Pharmaust P/E
-3.88
Ticker
PAA.AX
ISIN
AU000000PAA1
WKN
A0DNJ3
As of Sep 10, 2024, Pharmaust's P/E ratio was -3.88, a -76.5% change from the -16.51 P/E ratio recorded in the previous year.
The Pharmaust P/E history
Pharmaust Aktienanalyse
What does Pharmaust do?
Pharmaust Ltd is a biotechnology company based in Perth, Australia. The company was founded in 2001 by Dr. Roger Aston and Dr. Paul Gavin as a spin-off from the School of Biomedical Sciences at Curtin University of Technology. Their goal was to advance the discovery and development of novel therapeutics and diagnostics for cancer and autoimmune diseases. Pharmaust's history began with the discovery of a novel molecule called PPL-1 by Dr. Roger Aston. This molecule had the potential to serve as a cancer therapeutic as it could inhibit the release of tumor cells. Pharmaust researchers held patents for PPL-1 in the US, Europe, and Australia. Another important milestone for Pharmaust was the discovery of a new class of compounds with potential cancer and autoimmune therapeutics known as PPL-100, PPL-300, and PPL-400. Pharmaust's business model is focused on bringing novel drugs and diagnostics to market and selling them. Pharmaust aims to use its technologies to reduce the high costs of drug research and ultimately help patients suffering from serious diseases. Pharmaust has several divisions, including: - Pharmaceutical research and development: Pharmaust is working to discover and develop new therapeutics and diagnostics, particularly for the treatment of cancer and autoimmune diseases. - Clinical research: Pharmaust conducts clinical trials to assess the safety and efficacy of its drugs and obtain the necessary approvals for market authorization. - Licensing and marketing: Pharmaust markets its products in Australia and other countries, and licenses its technologies to other biopharmaceutical companies to generate additional revenue. Pharmaust's current product portfolio includes two main products sold under the brand names Monepantel and PPL-003. Monepantel is an anthelmintic used to treat parasite infestation in livestock such as sheep and goats. PPL-003 is an immunotherapy for the treatment of skin cancer, currently being tested in clinical trials. In particular, Pharmaust has developed a therapy in recent years that supports immunotherapy and works closely with clinics and payers to further develop and market their therapy. Pharmaust has received numerous awards and recognitions in recent years, including the award for Perth's Best Emerging Company and recognition from the Western Australian Industry and Export Awards (WAIEA) and the Australasian Society for Stem Cell Research (ASSCR). In conclusion, Pharmaust Ltd remains committed to saving and improving lives. The company sees a promising future in the discovery, development, and marketing of novel therapeutics and diagnostics for the treatment of serious diseases. By integrating four different drug classes, Pharmaust is working on a range of early-stage development projects that have the potential to help patients suffering from various diseases. Pharmaust ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/E Details
Deciphering Pharmaust's P/E Ratio
The Price to Earnings (P/E) Ratio of Pharmaust is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.
Year-to-Year Comparison
Assessing Pharmaust's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.
Impact on Investments
The P/E ratio of Pharmaust is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.
Interpreting P/E Ratio Fluctuations
Fluctuations in Pharmaust’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.
Frequently Asked Questions about Pharmaust stock
How has the price-earnings ratio of Pharmaust changed compared to last year?
The price-to-earnings ratio of Pharmaust has increased by -76.5% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Pharmaust high compared to other companies?
Yes, the price-to-earnings ratio of Pharmaust is high compared to other companies.
How does an increase in the price-earnings ratio of Pharmaust affect the company?
An increase in the price-earnings ratio of Pharmaust would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Pharmaust affect the company?
A decrease in the price-earnings ratio of Pharmaust would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Pharmaust?
Some factors that influence the price-earnings ratio of Pharmaust are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Pharmaust pay?
Over the past 12 months, Pharmaust paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pharmaust is expected to pay a dividend of 0 AUD.
What is the dividend yield of Pharmaust?
The current dividend yield of Pharmaust is .
When does Pharmaust pay dividends?
Pharmaust pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Pharmaust?
Pharmaust paid dividends every year for the past 0 years.
What is the dividend of Pharmaust?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Pharmaust located?
Pharmaust is assigned to the 'Health' sector.
Wann musste ich die Aktien von Pharmaust kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Pharmaust from 9/10/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.
When did Pharmaust pay the last dividend?
The last dividend was paid out on 9/10/2024.
What was the dividend of Pharmaust in the year 2023?
In the year 2023, Pharmaust distributed 0 AUD as dividends.
In which currency does Pharmaust pay out the dividend?
The dividends of Pharmaust are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Pharmaust
Our stock analysis for Pharmaust Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharmaust Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
